Health Care • Biotechnology: Pharmaceutical Preparations
$20.86 ▲ +0.29
(+1.41%)
MKT CAP: $424.7M • VOL: 198.8K
52W L $19 52W H $40
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$18
MEDIAN
$23
MEAN
$24
HIGH
$28
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ASMB TAPE
ASMB // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $25.24 | $23.99 | 2025-02-14 | $18.98 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $26.28 | $24.61 | 2025-02-06 | $19.61 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $23.78 | $22.95 | 2025-01-29 | $20.03 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $21.28 | — | 2025-01-17 | $20.44 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $18.36 | $19.82 | 2025-01-09 | $18.57 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $24.82 | $21.69 | 2024-12-18 | $18.15 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $20.23 | $21.07 | 2024-12-04 | $19.40 | -4.3% | 48% | C |